Search results
Moderna unveils robust next-gen COVID-19 vaccine pipeline progress By Investing.com
Investing.com· 2 days agoThe company expects regulatory approval and U.S. launch for its RSV vaccine in 2024, following...
Moderna Gets $750 Million for Flu Program to Help Move Beyond Covid Vaccines
Barrons.com· 2 days ago“Achieving this ambition requires substantial investment in late-stage studies and we are excited...
Moderna shares continue to fall even as its 3 vaccines enter final stage trials | Invezz
Invezz· 1 day agoModerna Inc. saw its stock continue its downward trajectory on Wednesday, slipping by 1.2% to...
Moderna’s new and improved COVID vaccine produced positive trial results
Market Watch· 3 days agoModerna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results...
Moderna Says 'Next-Generation' COVID-19 Shot Had Positive Phase 3 Test Results
Investopedia· 2 days agoChief Executive Officer (CEO) Stephane Bancel explained that mRNA-1283 is a “critical component” of...
Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
Simply Wall St. via Yahoo Finance· 7 days agoHowever, while insider selling is sometimes discouraging, it's only a weak signal. We note that the...
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
CNBC· 2 days agoModerna has more to offer beyond its Covid vaccine. The biotech company Wednesday announced positive...
Blackstone to Fund Moderna's Flu Research With up to $750 Million
Morningstar· 2 days agoBlackstone has agreed to fund up to $750 million of Moderna's research to develop a vaccine for influenza in return for royalties and payouts based on certain ...
Moderna gets Blackstone backing for flu vaccine R&D
BioPharma Dive via Yahoo Finance· 2 days ago“Our goal is to launch multiple vaccine products in the next few years and deliver the greatest possible impact to people through mRNA medicines,” said ...
Moderna secures $750 million from Blackstone Life Sciences to develop flu shots
AOL· 2 days agoThe biotech firm is developing several new vaccines, including for cancer and respiratory syncytial virus (RSV), and plans to spend about $4.5 billion on ...